| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Departments of Medicine and Pathology [Y. Z., J. H.], University of Chicago, Chicago, Illinois 60637 [Y. Z., J. H.], and Department of Medicine [F. C. v. L., N. V., G. R. B.], University of California, San Diego, California 92093 [M. B., S. K., R. K. W., L. N., S. S., T. A. B.]
Azoxymethane (AOM)-induced colonic carcinogenesis involves a number of mutations, including those in the K-ras gene and CTNNB1, that codes for ß-catenin. Prior in vitro studies have also demonstrated that wild type p21K-ras can be activated by epigenetic events. We identified 15 K-ras mutations in 14 of 84 AOM-induced colonic tumors by three independent methods. By single strand conformational polymorphism, we also observed mutations in 22 of 68 tumors in exon 3 of CTNNB1. A highly sensitive method was then used to measure p21ras activation levels. All tumors assayed possessing K-ras mutations had significantly higher p21ras activation levels (8.8 ± 1.5%; n = 13) compared with that of control colon (3.7 ± 0.4; n = 6; P < 0.05) or tumors without such mutations (4.2 ± 0.4%; n = 70; P < 0.05). Among tumors with wild-type K-ras, there was a subset of tumors (18 of 70) that had significantly higher p21ras activation levels (8.0 ± 0.9%; n = 18) compared with control colons. In three of four tumors examined with activated wild-type p21ras, we observed increased c-erbB-2 receptor expression and decreased Ras-GAP expression. In contrast, only one of eight tumors examined with wild-type ras and nonactivated p21ras demonstrated these alterations. Mitogen-activated protein kinase (MAPK) activation and cyclooxygenase-2 (COX-2) expression were increased in tumors with mutated or activated wild-type p21ras, compared with their nonactivated counterparts. Although ß-catenin mutations did not alter COX-2 expression or MAPK activity, mutations in either K-ras or ß-catenin significantly increased cyclin D1 expression. In contrast, in tumors with wild-type but activated p21ras, cyclin D1 expression was not enhanced. Thus, the spectrum of changes in MAPK, COX-2, and cyclin D1 is distinct among tumors with ras or ß-catenin mutations or nonmutational activation of p21ras.
This article has been cited by other articles:
![]() |
U. Dougherty, D. Cerasi, I. Taylor, M. Kocherginsky, U. Tekin, S. Badal, L. Aluri, A. Sehdev, S. Cerda, R. Mustafi, et al. Epidermal Growth Factor Receptor Is Required for Colonic Tumor Promotion by Dietary Fat in the Azoxymethane/Dextran Sulfate Sodium Model: Roles of Transforming Growth Factor-{alpha} and PTGS2 Clin. Cancer Res., November 15, 2009; 15(22): 6780 - 6789. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. Rosenberg, C. Giardina, and T. Tanaka Mouse models for the study of colon carcinogenesis Carcinogenesis, February 1, 2009; 30(2): 183 - 196. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tao, J. Hart, L. Lichtenstein, L. J. Joseph, M. J. Ciancio, S. Hu, E. B. Chang, and M. Bissonnette Inducible heat shock protein 70 prevents multifocal flat dysplastic lesions and invasive tumors in an inflammatory model of colon cancer Carcinogenesis, January 1, 2009; 30(1): 175 - 182. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Lurje, F. Nagashima, W. Zhang, D. Yang, H. M. Chang, M. A. Gordon, A. El-Khoueiry, H. Husain, P. M. Wilson, R. D. Ladner, et al. Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab Clin. Cancer Res., December 1, 2008; 14(23): 7884 - 7895. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Dougherty, A. Sehdev, S. Cerda, R. Mustafi, N. Little, W. Yuan, S. Jagadeeswaran, A. Chumsangsri, J. Delgado, M. Tretiakova, et al. Epidermal Growth Factor Receptor Controls Flat Dysplastic Aberrant Crypt Foci Development and Colon Cancer Progression in the Rat Azoxymethane Model Clin. Cancer Res., April 15, 2008; 14(8): 2253 - 2262. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Fichera, N. Little, S. Jagadeeswaran, U. Dougherty, A. Sehdev, R. Mustafi, S. Cerda, W. Yuan, S. Khare, M. Tretiakova, et al. Epidermal Growth Factor Receptor Signaling Is Required for Microadenoma Formation in the Mouse Azoxymethane Model of Colonic Carcinogenesis Cancer Res., January 15, 2007; 67(2): 827 - 835. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Khare, C. Holgren, and A. M. Samarel Deoxycholic acid differentially regulates focal adhesion kinase phosphorylation: role of tyrosine phosphatase ShP2 Am J Physiol Gastrointest Liver Physiol, December 1, 2006; 291(6): G1100 - G1112. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Cohen, R. Mustafi, A. Chumsangsri, N. Little, J. Nathanson, S. Cerda, S. Jagadeeswaran, U. Dougherty, L. Joseph, J. Hart, et al. Epidermal Growth Factor Receptor Signaling Is Up-regulated in Human Colonic Aberrant Crypt Foci Cancer Res., June 1, 2006; 66(11): 5656 - 5664. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. T. Tran, D. Naigamwalla, A. I. Oprescu, L. Lam, G. McKeown-Eyssen, W. R. Bruce, and A. Giacca Hyperinsulinemia, But Not Other Factors Associated with Insulin Resistance, Acutely Enhances Colorectal Epithelial Proliferation in Vivo Endocrinology, April 1, 2006; 147(4): 1830 - 1837. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Wang, F. G. Buchanan, H. Wang, S. K. Dey, and R. N. DuBois Prostaglandin E2 Enhances Intestinal Adenoma Growth via Activation of the Ras-Mitogen-Activated Protein Kinase Cascade Cancer Res., March 1, 2005; 65(5): 1822 - 1829. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Du, B. Jiang, R. J. Coffey, and J. Barnard Raf and RhoA Cooperate to Transform Intestinal Epithelial Cells and Induce Growth Resistance to Transforming Growth Factor {beta} Mol. Cancer Res., April 1, 2004; 2(4): 233 - 241. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Khare, S. Cerda, R. K. Wali, F. C. von Lintig, M. Tretiakova, L. Joseph, D. Stoiber, G. Cohen, K. Nimmagadda, J. Hart, et al. Ursodeoxycholic Acid Inhibits Ras Mutations, Wild-type Ras Activation, and Cyclooxygenase-2 Expression in Colon Cancer Cancer Res., July 1, 2003; 63(13): 3517 - 3523. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Gotoh, M. Obata, M. Yoshie, S. Kasai, and K. Ogawa Cyclin D1 over-expression correlates with {beta}-catenin activation, but not with H-ras mutations, and phosphorylation of Akt, GSK3{beta} and ERK1/2 in mouse hepatic carcinogenesis Carcinogenesis, March 1, 2003; 24(3): 435 - 442. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Wali, S. Khare, M. Tretiakova, G. Cohen, L. Nguyen, J. Hart, J. Wang, M. Wen, A. Ramaswamy, L. Joseph, et al. Ursodeoxycholic Acid and F6-D3 Inhibit Aberrant Crypt Proliferation in the Rat Azoxymethane Model of Colon Cancer: Roles of Cyclin D1 and E-Cadherin Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1653 - 1662. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. D. Girnun, W. M. Smith, S. Drori, P. Sarraf, E. Mueller, C. Eng, P. Nambiar, D. W. Rosenberg, R. T. Bronson, W. Edelmann, et al. APC-dependent suppression of colon carcinogenesis by PPARgamma PNAS, October 15, 2002; 99(21): 13771 - 13776. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Tsunozaki, K. Yoshinaga, J. Kumagai, and K. Sugihara Cyclooxygenase-2 Overexpression in Colorectal Cancer is Associated with Non-polypoid Growth Jpn. J. Clin. Oncol., May 1, 2002; 32(5): 167 - 171. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Domon-Dell, Q Wang, S Kim, M Kedinger, B M Evers, and J-N Freund Stimulation of the intestinal Cdx2 homeobox gene by butyrate in colon cancer cells Gut, April 1, 2002; 50(4): 525 - 529. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. A. C. S. Wong and M. Pignatelli {beta}-Catenin--A Linchpin in Colorectal Carcinogenesis? Am. J. Pathol., February 1, 2002; 160(2): 389 - 401. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Shono, P. J. Tofilon, J. M. Bruner, O. Owolabi, and F. F. Lang Cyclooxygenase-2 Expression in Human Gliomas: Prognostic Significance and Molecular Correlations Cancer Res., June 1, 2001; 61(11): 4375 - 4381. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |